During this weekend, have met in Seville the best European specialists of different medical specialties in allergy, internal medicine, dermatology and emergency care to share their knowledge of angioedema, a disease that can cause death and that is underdiagnosed, as has been discussed these experts. In addition, patients affected by this pathology have also attended some of these days-urgently require access to new drugs that are present in Spain since by bureaucratic fear they will not have easy access to medication and have reported that during the past two months, have felt totally helpless.
● The experts reveal that Spain has been one of those European countries that has received a grant to investigate this complex disease that has three variants and is usually confused with an allergy. European specialists have explained in these days that is necessary to train the earliest health professionals in the diagnosis and treatment of this disease are currently analyzing the genetic causes of the three subtypes (Type I, II and III).
● This condition is underdiagnosed and only 45% of patients across Europe are correctly diagnosed and treated, according to Dr. Marco said Cicardi, Head of the Unit of Internal Medicine Hospital Luigi Sacco, Italy.
● Angioedema is a serious disease that affects an estimated 1/10.000 or 1:50,000 individuals worldwide. This means only the European Union may have 75,000 people who are affected by this disease. There are many people who suffer from GAD at some point in their lives and are unaware they have it, because it usually coincides with an allergy sporadic, as there are patients who may have few episodes throughout life.
● These inflammatory episodes may occur independently or together in the glottis, face, mucous, abdomen, limbs or internal organs like the appendix or bowel. These inflammatory processes are very serious and sometimes can be confused with other allergic diseases. There are patients who have been slow to diagnose the disease twenty years and have always thought they were allergic.
Angioedema is an underdiagnosed disease and is estimated to affect one in 10,000 to 50,000 patients in Europe and USA. Currently, only 45% of people suffering from this disease in Europe are correctly diagnosed and treated, said Marco Cicardi, Head of the Unit of Internal Medicine Hospital Luigi Sacco, Italy, in a conference held during this weekend Virgen del Rocio Hospital in Seville and have participated in the great references from all over Europe in different fields as Allergology, Internal Medicine, Emergency, Dermatology and Genetics.
These specialists have also highlighted the presence of Dr. Konrad Bork, a researcher at the Department of Dermatology, University of Mainz, Dr. S. Cichon, Researcher Geneticist Genomics, Department of Brain Center, University of Bonn, Germany and Dr. H. Professor Farkas Semmelweiss University, Budapest, Hungary; all coordinators of multiple research projects on this disease and other inflammatory-based diseases.
By Spain, has highlighted the presence of Dr. Teresa Gonzalez-Quevedo Tejerina, an allergist at the Hospital Virgen del Rocío de Sevilla, who has stated that, currently in Spain, there are about 800 families diagnosed, of which 206 belong to Andalusia and has alerted his colleagues that doctors surely there are many more families without a diagnosis in our country, because this disease in some of its subtypes as in the class II and III-often mistaken for an episode of allergy time. The aim of this conference is to train all possible medical specialists in knowledge, diagnosis and treatment of this disease as hereditary angioedema is an underdiagnosed disease not uncommon, because many people who suffer and do not know that the suffer and therefore is of low prevalence, Gonzalez-Quevedo said.
This view was shared by other specialists. For his part, Dr. Mark Cicardi said Europe is ahead in the investigation of this disease thanks to European Union aid. Spain is one of ten European countries that have received EU subsidies in recent years to investigate Angioedema with Italy, Denmark, France, Germany, Norway, Poland, Switzerland and United Kingdom. Therefore, Dr. Cicardi revealed that, thanks to these aids are created in Spain hospital groups of researchers and reference in the diagnosis and treatment of this disease. In Europe we have a unique opportunity to advance in the genetic diagnosis of this disease in the U.S. and, therefore, to prevent many deaths and episodes of angioedema. And, he added, "It is necessary to train medical specialists in allergy, immunology, pulmonology, internal medicine, otolaryngology, gastrointestinal specialists and nephrology at the correct diagnosis of this disease, because many bodies may be affected sporadically and not angioedema necessarily have to be present at all, said the Italian internist.
Dr. Gonzalez-Quevedo Tejerina Seville, said that in severe cases the disease can trigger critical tables to ignite the glottis, pharynx, or certain parts of the respiratory system can potentially have a fatal outcome for the patient. Fortunately, we have the good fortune to be able to diagnose this disease with new genetic markers and dealing with new treatments. Diagnose addition we need access to more training on the different therapeutic options with which we have and when to apply depending on the type of patient and emerging new scientific advances that help us to better therapeutic targets, reiterated this Doctor of the Hospital Virgen del Rocio.
As pointed out by Dr. Sven Cichon, Assistant Professor of Human Genetics at the Institute of Human Genetics at the Life and Brain Center, University of Bonn, Germany, one of the reasons for this underdiagnosis has been the difficulty of the when classifying subtypes within the disease, since there are three types of hereditary angioedema. Hereditary angioedema type I, type II hereditary angioedema and hereditary angioedema type III. For this doctor, patients with type I, presented in its analytical shortcomings in the protein called C1 inhibitor estarasa and also observed a mutation on chromosome 11. In the class II Angioedema, C1 levels inhibor are correct, but this enzyme does not perform its function properly and is usually observed a mutation on chromosome 12. Finally, the angioedema type III, C1 inhibitor levels are normal, and the rest of the chromosomes without mutations occur, but it is believed that this subtype III is hormone-dependent, ie it is related to estrogen level in the patient and specifically in this subclass, the German experts in genetics, are perhaps studying a possible mutation on chromosome 5 in this subtype.
Self-care information program
Anyway, in the three types of angioedema disease can be fatal in some of the episodes and it is necessary to diagnose it early and take preventive measures to prevent such crises and involving patients in self-management programs that do not live with panic, pinpointed all the experts present.
In the words of Dr. Gonzalez-Quevedo, the type III hereditary angioedema are the most difficult to classify and are often confused with a specific allergy to a substance. Therefore, any person who has suffered an episode of angioedema in their life should ask to be carried out appropriate tests to rule out suffering any of the three existing types of hereditary angioedema and participate as far as possible in their self-serving a series of recommendations to prevent one of these attacks, said the doctor.
Affected patients speak
Commenting on the magic word self-care, some patients suffering from these ailments value expressed their opinion in open to specialists. We are afraid of not having the medication on time, since we know that the EMEA has approved new drugs but in some hospitals in Spain, for various reasons, still do not. Then, "We are afraid of suffering a serious crisis and we can not treat. Faced with a serious crisis of angioedema we only have two drugs, one of them is alien to medicine that involves red tape and the other, Firazyr is not yet in many hospitals. I was not prepared to live in fear and before I decided to get my personal situation in Germany and now I'm much calmer, said Mercedes Blanco, patients with this condition.
Given these statements, Dr. Teresa Gonzalez-Quevedo and Dr. Stefan Cimbollek, both members of the Department of Allergology Hospital Virgen del Rocío explained to patients who expected this situation will be normalized since May, hope that very soon our Departments hospital pharmacy help us process all necessary steps to have all the resources possible battery which already exist in Spain to deal a serious crisis in patients with hereditary angioedema, argued these doctors.
As noted by the team of Angioedema in Italy, this new active ingredient, Icatibant acetate will be presented as a prefilled syringe and represents a revolution in the fast approach to this condition, because being a synthetic substance reduces the risks, as such as infections, involving far plasma derivatives injected intravenously. This is a simple subcutaneous injection under the skin-much easier to make and early relief of symptoms occurs in a median time of 48 minutes, which will revolutionize patient self-care, said Cicardi.
Then the group of patients from Andalusia in relation to these statements by experts, proposed the idea of creating a group of self-care of patients with allergies belonging exclusively to the zone of Andalucía. Idea which was warmly welcomed by most of the specialists who were present and which inspired a new political issue as to the responsibilities of each community and government aid to deliver only the entities belonging to their community, rather than give them to the national office. I do not agree that local groups are created on this disease, because we must be together in one country, and it seems unfair that just because we divide the given economic aid each Autonomous Community. If we are divided we lose strength because each pull to one side as is already happening at other levels in Spain, said Sara Smith, President of the Spanish Association of Patients with Hereditary Angioedema Familiar.
Friday, August 28, 2009
About 400 women from Bizkaia have controlled pregnancy and pregnancy Psicofármacos Unit of the Psychiatric Service of Hospital de Cruces.
About 400 women from Bizkaia have controlled pregnancy and pregnancy Psicofármacos Unit of the Psychiatric Service of Hospital de Cruces.
The Unit has not detected by use of psychotropic medication problems beyond the normal casuistry, which expresses the guarantee offered maintenance treatment under control.
The Psychoactive Drugs and Pregnancy Unit of the Psychiatric Service of Hospital de Cruces which coordinates Robador Ana psychiatrist has, since 2000, the date of its foundation in a referral center for women who want to stay or have become pregnant suffer mental pathology. Over the past eight years around 400 women have taken the course of her pregnancy under close monitoring of that unit, immersed in the category of pathological pregnancies and the interaction of various specialists. It is the best way to control the whole process, says the coordinator of the Unit, Psychiatry Service dependent but closely related, in turn, with the Department of Obstetrics and Gynecology and Neonatology of the Hospital.
In these and other issues Robador Ana speech at the conference's closing day organized by the extraordinary Basque-Navarra of Psychiatry. Throughout this period, the Unit has not encountered problems by use of psychotropic medication beyond the normal casuistry, which expresses the guarantee offered maintenance treatment under control. Ana Robador said, though, that when it can not all cases seen are of the same gravity-medication is recommended as little as possible in the first trimester of pregnancy.
It is a simple matter. Many patients come to the Hospital de Cruces derived from other schools and when they are pregnant. Perhaps not noticed the pregnancy until after the first month and during this period have been medicated. That is why the unit has begun to recommend pregnancy planning to withdraw the drugs of greatest risk.
Ana Robador emphasizes that not all cases treated in the unit due to severe psychiatric disorders, which are those that require closer monitoring. There are also women who have, for example, moderate anxiety disorders that require specific monitoring of her pregnancy.
The Unit has not detected by use of psychotropic medication problems beyond the normal casuistry, which expresses the guarantee offered maintenance treatment under control.
The Psychoactive Drugs and Pregnancy Unit of the Psychiatric Service of Hospital de Cruces which coordinates Robador Ana psychiatrist has, since 2000, the date of its foundation in a referral center for women who want to stay or have become pregnant suffer mental pathology. Over the past eight years around 400 women have taken the course of her pregnancy under close monitoring of that unit, immersed in the category of pathological pregnancies and the interaction of various specialists. It is the best way to control the whole process, says the coordinator of the Unit, Psychiatry Service dependent but closely related, in turn, with the Department of Obstetrics and Gynecology and Neonatology of the Hospital.
In these and other issues Robador Ana speech at the conference's closing day organized by the extraordinary Basque-Navarra of Psychiatry. Throughout this period, the Unit has not encountered problems by use of psychotropic medication beyond the normal casuistry, which expresses the guarantee offered maintenance treatment under control. Ana Robador said, though, that when it can not all cases seen are of the same gravity-medication is recommended as little as possible in the first trimester of pregnancy.
It is a simple matter. Many patients come to the Hospital de Cruces derived from other schools and when they are pregnant. Perhaps not noticed the pregnancy until after the first month and during this period have been medicated. That is why the unit has begun to recommend pregnancy planning to withdraw the drugs of greatest risk.
Ana Robador emphasizes that not all cases treated in the unit due to severe psychiatric disorders, which are those that require closer monitoring. There are also women who have, for example, moderate anxiety disorders that require specific monitoring of her pregnancy.
refresher course in ophthalmology
Fernandez-Vega Institute will present its third professionals engaged in the research phase for a refresher course in ophthalmology.
Prestigious ophthalmologists attend this conference to be held on 8 and 9 May. Know the new facilities and will make a major update on solutions to major eye diseases.
Following the recent opening of the third institutional phase Fernández-Vega Ophthalmological Institute by Their Majesties King, the center will host the next days 8 and 9 May, a Refresher Course in Ophthalmology, congress will present to the ophthalmologists new facilities dedicated to basic research. The meeting, which will serve its audience to catch up on the major advances achieved in recent years in all or almost all ophthalmic disciplines, will also address important issues that already begun research in the center, including new techniques and treatment of glaucoma and other diseases common in the cornea and retina.
The course, attended by two hundred experts from around the world, is led by Professor Luis Fernández-Vega Sanz, director of the Eye Institute, and is divided into the following six sessions (led by doctors at each of them are listed ) Supeficie eye (doctors and Begoña Baamonde Jesus Merayo Arbaiza) Cornea and refractive (José F. Alfonso Sanchez and Mariano Sanchez Yllera), Cataract (Luis Fernández-Vega Sanz and Jose I. Blázquez García), Orbit and appendages (Javier Fernandez -Vega Sanz), Glaucoma (Pedro Pablo Martín and Manuel Calvo Riano Granero) and Retina (Álvaro Fernández-Vega Sanz).
Institute director, Luis Fernández-Vega Sanz, considered appropriate that the opening of the third phase had not only some institutional (or social) but held a medical activity that would serve, in turn, to present to the world of Medicine is pioneering basic research unit in Europe in which they have invested six million euros and which employs more than twenty internationally renowned specialists.
Six working sessions
The first session (Supeficie eye) will try to update the most common problems of the ocular surface, such as dry eye or ocular allergies, which cause discomfort (feeling of sand, stinging, itching) and can reduce vision and affect the quality of life of patients and more rare diseases such as ocular manifestations of systemic diseases such as rheumatic or immunological. It will review the prevention, medical and surgical treatment and regenerative medicine will address the ocular surface with the update of transplantation techniques and reconstruction of the cornea, eyelids and conjunctiva.
The second (Cornea and Refractive) address laser surgical techniques and intraocular lenses. On the latter must be said that existing lenses that correct presbyopia and any other defect of graduation. Of them should also highlight that ICLs phakic lenses and can correct most refractive errors: myopia, hipermetromía, astigmatism, etc.. Previously, only solved the first. It is indicated for patients unable to tolerate the laser.
The third meeting (Waterfall), will display new bifocals will present Luis Fernández-Vega Sanz. These lenses improvements to existing ones because they produce better intermediate vision. Also present at this meeting lenses (IOLs) with adjustable light.
The fourth session (Orbit and appendages) will focus on major developments on practical techniques in Ocular Plastic Surgery. Keep in mind that cosmetic surgery that is practiced today in most Western countries are related in a direct way with the eyes, especially the eyelids, orbits and tear ducts.
About Glaucoma (fifth session) will be discussed in depth on the new tools for early diagnosis of the disease (one of the main works to be carried out in the basic research unit of the Institute). It will also address new and better surgical techniques and implants perforating sclerectomy not valvular in glaucoma treatment.
In the last session (Retina) will discuss the progress made in recent years to resolve the macular degeneration associated with age, which is the leading cause of blindness in people over 60 years, which affects, from this age to 7% of world population.
Prestigious ophthalmologists attend this conference to be held on 8 and 9 May. Know the new facilities and will make a major update on solutions to major eye diseases.
Following the recent opening of the third institutional phase Fernández-Vega Ophthalmological Institute by Their Majesties King, the center will host the next days 8 and 9 May, a Refresher Course in Ophthalmology, congress will present to the ophthalmologists new facilities dedicated to basic research. The meeting, which will serve its audience to catch up on the major advances achieved in recent years in all or almost all ophthalmic disciplines, will also address important issues that already begun research in the center, including new techniques and treatment of glaucoma and other diseases common in the cornea and retina.
The course, attended by two hundred experts from around the world, is led by Professor Luis Fernández-Vega Sanz, director of the Eye Institute, and is divided into the following six sessions (led by doctors at each of them are listed ) Supeficie eye (doctors and Begoña Baamonde Jesus Merayo Arbaiza) Cornea and refractive (José F. Alfonso Sanchez and Mariano Sanchez Yllera), Cataract (Luis Fernández-Vega Sanz and Jose I. Blázquez García), Orbit and appendages (Javier Fernandez -Vega Sanz), Glaucoma (Pedro Pablo Martín and Manuel Calvo Riano Granero) and Retina (Álvaro Fernández-Vega Sanz).
Institute director, Luis Fernández-Vega Sanz, considered appropriate that the opening of the third phase had not only some institutional (or social) but held a medical activity that would serve, in turn, to present to the world of Medicine is pioneering basic research unit in Europe in which they have invested six million euros and which employs more than twenty internationally renowned specialists.
Six working sessions
The first session (Supeficie eye) will try to update the most common problems of the ocular surface, such as dry eye or ocular allergies, which cause discomfort (feeling of sand, stinging, itching) and can reduce vision and affect the quality of life of patients and more rare diseases such as ocular manifestations of systemic diseases such as rheumatic or immunological. It will review the prevention, medical and surgical treatment and regenerative medicine will address the ocular surface with the update of transplantation techniques and reconstruction of the cornea, eyelids and conjunctiva.
The second (Cornea and Refractive) address laser surgical techniques and intraocular lenses. On the latter must be said that existing lenses that correct presbyopia and any other defect of graduation. Of them should also highlight that ICLs phakic lenses and can correct most refractive errors: myopia, hipermetromía, astigmatism, etc.. Previously, only solved the first. It is indicated for patients unable to tolerate the laser.
The third meeting (Waterfall), will display new bifocals will present Luis Fernández-Vega Sanz. These lenses improvements to existing ones because they produce better intermediate vision. Also present at this meeting lenses (IOLs) with adjustable light.
The fourth session (Orbit and appendages) will focus on major developments on practical techniques in Ocular Plastic Surgery. Keep in mind that cosmetic surgery that is practiced today in most Western countries are related in a direct way with the eyes, especially the eyelids, orbits and tear ducts.
About Glaucoma (fifth session) will be discussed in depth on the new tools for early diagnosis of the disease (one of the main works to be carried out in the basic research unit of the Institute). It will also address new and better surgical techniques and implants perforating sclerectomy not valvular in glaucoma treatment.
In the last session (Retina) will discuss the progress made in recent years to resolve the macular degeneration associated with age, which is the leading cause of blindness in people over 60 years, which affects, from this age to 7% of world population.
ASEFARMA pharmacists report on the swine flu.
Asefarma, together with pharmacies in Madrid, has produced a brochure to advise anyone who has doubts Cities @.
With this initiative seek to collaborate for the hospital emergency room or not to collapse before the pandemic alert
Information is the best recipe to prevent. Therefore, in the 300 pharmacies in Madrid ASEFARMA attached, the main Pharmacy Consulting Spain, has just been put in place an action that will relieve more than one. Our pharmacists will provide information to any citizen who has questions about what this virus and what to do, says Carlos Garcia-Mauriño, managing partner of Asefarma. In this way we transmit to society calm and Spanish health authorities have demonstrated their expertise and have all the control mechanisms to quickly identify and monitor cases of people affected, he adds.
And the possibility is that, as recently announced by WHO (World Health Organization) of a global pandemic, the work of pharmacies reveals fundamental. First because of its proximity to the citizen virtually the entire population is a pharmacy within 300 meters from his home, second as a clearinghouse for antiviral drugs etc, and third as health professionals in informing and advising. The current law governing pharmacies in Spain and its conception as part of our National Health System angels are revealed in these times of uncertainty, added Garcia-Maurin.
This being the pharmacists will place special emphasis on explaining that the drugs needed to kill the virus are the same as those used in typical flu. These antivirals have side effects that are only released with a prescription.
As for the doubts that the pharmacists will clear to citizens that they will want to attend, including:
- What is the swine flu and how is it spread?
- Are the swine influenza virus can infect humans?
- What are the symptoms?
- Does the swine influenza virus H1N1 is equal to the H1N1 influenza virus in humans?
- How is diagnosed swine flu infections in humans?
- Is the current vaccine protects against seasonal influenza flu type H1N1 porcine origin?
- Are there medicines to treat people infected with swine influenza viruses?
- What is done to detect other cases of infections in people with the virus H1N1 swine influenza once it has detected a case?
On the other hand since it Asefarma advised in pharmacies where masks to protect themselves from acquiring 100% of viruses - and they are the same ones that are already spreading in hospitals, since they, not others be purchased in other shops, meet European standards for which they are made and are proof of sneezing, socio-end Asefarma director.
With this initiative seek to collaborate for the hospital emergency room or not to collapse before the pandemic alert
Information is the best recipe to prevent. Therefore, in the 300 pharmacies in Madrid ASEFARMA attached, the main Pharmacy Consulting Spain, has just been put in place an action that will relieve more than one. Our pharmacists will provide information to any citizen who has questions about what this virus and what to do, says Carlos Garcia-Mauriño, managing partner of Asefarma. In this way we transmit to society calm and Spanish health authorities have demonstrated their expertise and have all the control mechanisms to quickly identify and monitor cases of people affected, he adds.
And the possibility is that, as recently announced by WHO (World Health Organization) of a global pandemic, the work of pharmacies reveals fundamental. First because of its proximity to the citizen virtually the entire population is a pharmacy within 300 meters from his home, second as a clearinghouse for antiviral drugs etc, and third as health professionals in informing and advising. The current law governing pharmacies in Spain and its conception as part of our National Health System angels are revealed in these times of uncertainty, added Garcia-Maurin.
This being the pharmacists will place special emphasis on explaining that the drugs needed to kill the virus are the same as those used in typical flu. These antivirals have side effects that are only released with a prescription.
As for the doubts that the pharmacists will clear to citizens that they will want to attend, including:
- What is the swine flu and how is it spread?
- Are the swine influenza virus can infect humans?
- What are the symptoms?
- Does the swine influenza virus H1N1 is equal to the H1N1 influenza virus in humans?
- How is diagnosed swine flu infections in humans?
- Is the current vaccine protects against seasonal influenza flu type H1N1 porcine origin?
- Are there medicines to treat people infected with swine influenza viruses?
- What is done to detect other cases of infections in people with the virus H1N1 swine influenza once it has detected a case?
On the other hand since it Asefarma advised in pharmacies where masks to protect themselves from acquiring 100% of viruses - and they are the same ones that are already spreading in hospitals, since they, not others be purchased in other shops, meet European standards for which they are made and are proof of sneezing, socio-end Asefarma director.
Experts warn of consumer confusion generated by the continuous changes in nutrition messages.
Foundation Health Sciences, Instituto Tomás Pascual and Student Residence managing the Day of obesity to anorexia: controversies in current food
Food is being used almost as drugs-especially-called functional, so it would not hurt that these were all the healing properties attributed to them
The Mediterranean diet has shifted from largely unknown to become a panacea, although few studies with scientific evidence of its potential beneficial effects
Dissatisfaction with self-image arises primarily from the enormous social pressure and especially affects women
The generic communication and non-commercial training should only be done by government and academia, but also by agents of the Food Chain
There are bodies concerned in accordance with criteria that we feed upon them well, and not on what one should decide autonomously
What to eat? Today is the question that we do very often, when surrounded by palatable foods cheaper and easier to obtain, due to the uncertainty of whether they are good or bad, ie if we help to maintain health or, conversely, we ill will. Never before have we had so much information and at the time, so much confusion.
The food itself has ceased to be a natural to become very sophisticated that can be used in many ways, said Dr. Susana Monereo, Chief of Endocrinology and Nutrition Service of the Hospital de Getafe (Madrid) during the journey from obesity to anorexia: current controversies in food, organized by the Foundation for Health Sciences, Instituto Tomás Pascual Sanz and the Residencia de Estudiantes.
Using food wrongly by overinformation or lack of it, just taking a toll on our health in many ways, explains Monereo. In this regard, one of the objectives of the day, held today at the Residencia de Estudiantes, is to highlight the important role that food plays in our lives. Food is being used almost as drugs-especially-called functional, so it would not hurt that these were all the healing properties attributed to them, he adds.
According to Professor Gregorio Varela, Professor of Nutrition and Food Science, University CEU San Pablo, and president of the Spanish Nutrition Foundation, despite the advances in our knowledge, no other science-an allusion to nutrition, which is more surrounded by beliefs, myths and magic. During his lecture, entitled Truths and fallacies about the power of food, the expert had expressed surprise that such things happen more now than a hundred years ago.
The constant modification of the nutritional message in recent years has generated many times, mislead the consumer, explains Professor Varela. For example, the Mediterranean diet has gone from being a stranger to become a panacea, although few studies that show scientific evidence of its potential beneficial effects, he adds. Olive oil, fish and wine are some foods whose virtues have been globalized.
For his part, Dr. Clotilde Vazquez, head of the Clinical Nutrition Section of the Hospital Ramon y Cajal, Madrid, said that under eating disorders ranging from obesity to anorexia lies an abnormal relationship with food. They have a significant genetic basis, although dissatisfaction with the self-image arises primarily from the enormous social pressure, which particularly affects women, he notes.
Following this, young people are too drastic dieting. An exaggerated caloric restriction predisposes the organism to a subsequent rebound, which usually gain more weight than they lost and more fat, says the expert. Worryingly, increasingly, obesity is reached from the desire to lose weight, says Dr. Vazquez. Balance is in the normalization of the image as something quite different, not subject to external charges, and the improvement of the relationship with food.
Regarding the reliability of information and communication on food, José Ignacio Arranz, Interalimentario CEO Forum, a nonprofit association formed by 14 leading food companies, and former executive director of the Spanish Agency for Food Security and Nutrition has stressed the need to inform and educate the society on business communication, truth, excellence and scientific support.
During his lecture, entitled The information and communication on food, Arranz communication has suggested that generic non-commercial training and should only be done by government and academia, but also have to engage the operators of the food chain. In this sense, it is clear that businesses or business associations that come will be less challenged and the better your profile and increased its record of excellence, he concludes.
The ethical aspect of dietetics has been commissioned Professor Diego Gracia, Professor of History of Medicine at the Complutense University of Madrid and president of the Foundation for Health Sciences. There are many bodies involved in that nourish us according to criteria that suits them, and not on what one should make independent decisions, says the expert.
Professor Grace said that when the supply of products is so large, it is necessary to promote truthful reporting and accountability in the election: only mature personalities make the right decisions to get such a broad range of possibilities.
Tomás Pascual Sanz Institute for Nutrition and Health
Tomás Pascual Sanz Institute for Nutrition and Health is a non-profit organization created to promote research and training in the field of health and nutrition. Among others, are objectives of the Institute Tomás Pascual Sanz clinical research, collaboration with public authorities in nutritional programs, grants offered by scientific research, through agreements with various universities and the promotion of Environmental Management studies.
http://www.institutotomaspascual.es/
Foundation Health Sciences
Foundation Health Sciences is a nonprofit institution that seeks to be a meeting place for different social sectors involved in the world of health. Founded in 1991, its priority objectives revolve around bioethics, health, science and humanities, with a broad range of activities and projects.
Food is being used almost as drugs-especially-called functional, so it would not hurt that these were all the healing properties attributed to them
The Mediterranean diet has shifted from largely unknown to become a panacea, although few studies with scientific evidence of its potential beneficial effects
Dissatisfaction with self-image arises primarily from the enormous social pressure and especially affects women
The generic communication and non-commercial training should only be done by government and academia, but also by agents of the Food Chain
There are bodies concerned in accordance with criteria that we feed upon them well, and not on what one should decide autonomously
What to eat? Today is the question that we do very often, when surrounded by palatable foods cheaper and easier to obtain, due to the uncertainty of whether they are good or bad, ie if we help to maintain health or, conversely, we ill will. Never before have we had so much information and at the time, so much confusion.
The food itself has ceased to be a natural to become very sophisticated that can be used in many ways, said Dr. Susana Monereo, Chief of Endocrinology and Nutrition Service of the Hospital de Getafe (Madrid) during the journey from obesity to anorexia: current controversies in food, organized by the Foundation for Health Sciences, Instituto Tomás Pascual Sanz and the Residencia de Estudiantes.
Using food wrongly by overinformation or lack of it, just taking a toll on our health in many ways, explains Monereo. In this regard, one of the objectives of the day, held today at the Residencia de Estudiantes, is to highlight the important role that food plays in our lives. Food is being used almost as drugs-especially-called functional, so it would not hurt that these were all the healing properties attributed to them, he adds.
According to Professor Gregorio Varela, Professor of Nutrition and Food Science, University CEU San Pablo, and president of the Spanish Nutrition Foundation, despite the advances in our knowledge, no other science-an allusion to nutrition, which is more surrounded by beliefs, myths and magic. During his lecture, entitled Truths and fallacies about the power of food, the expert had expressed surprise that such things happen more now than a hundred years ago.
The constant modification of the nutritional message in recent years has generated many times, mislead the consumer, explains Professor Varela. For example, the Mediterranean diet has gone from being a stranger to become a panacea, although few studies that show scientific evidence of its potential beneficial effects, he adds. Olive oil, fish and wine are some foods whose virtues have been globalized.
For his part, Dr. Clotilde Vazquez, head of the Clinical Nutrition Section of the Hospital Ramon y Cajal, Madrid, said that under eating disorders ranging from obesity to anorexia lies an abnormal relationship with food. They have a significant genetic basis, although dissatisfaction with the self-image arises primarily from the enormous social pressure, which particularly affects women, he notes.
Following this, young people are too drastic dieting. An exaggerated caloric restriction predisposes the organism to a subsequent rebound, which usually gain more weight than they lost and more fat, says the expert. Worryingly, increasingly, obesity is reached from the desire to lose weight, says Dr. Vazquez. Balance is in the normalization of the image as something quite different, not subject to external charges, and the improvement of the relationship with food.
Regarding the reliability of information and communication on food, José Ignacio Arranz, Interalimentario CEO Forum, a nonprofit association formed by 14 leading food companies, and former executive director of the Spanish Agency for Food Security and Nutrition has stressed the need to inform and educate the society on business communication, truth, excellence and scientific support.
During his lecture, entitled The information and communication on food, Arranz communication has suggested that generic non-commercial training and should only be done by government and academia, but also have to engage the operators of the food chain. In this sense, it is clear that businesses or business associations that come will be less challenged and the better your profile and increased its record of excellence, he concludes.
The ethical aspect of dietetics has been commissioned Professor Diego Gracia, Professor of History of Medicine at the Complutense University of Madrid and president of the Foundation for Health Sciences. There are many bodies involved in that nourish us according to criteria that suits them, and not on what one should make independent decisions, says the expert.
Professor Grace said that when the supply of products is so large, it is necessary to promote truthful reporting and accountability in the election: only mature personalities make the right decisions to get such a broad range of possibilities.
Tomás Pascual Sanz Institute for Nutrition and Health
Tomás Pascual Sanz Institute for Nutrition and Health is a non-profit organization created to promote research and training in the field of health and nutrition. Among others, are objectives of the Institute Tomás Pascual Sanz clinical research, collaboration with public authorities in nutritional programs, grants offered by scientific research, through agreements with various universities and the promotion of Environmental Management studies.
http://www.institutotomaspascual.es/
Foundation Health Sciences
Foundation Health Sciences is a nonprofit institution that seeks to be a meeting place for different social sectors involved in the world of health. Founded in 1991, its priority objectives revolve around bioethics, health, science and humanities, with a broad range of activities and projects.
Treatment with zoledronic acid reduced the risk of relapse in women with breast cancer.
According to the results derived from this research zoledronic acid treatment would avoid the recurrence of breast cancer and 800 women in Spain every year
In Spain it is estimated that 25% of women with breast cancer who have been operated and subjected to standard adjuvant therapies, will have a relapse
Currently the drug is only indicated for prevention of complications of bone metastases, although research points to its ability to prevent relapses in other organs also
Treatment with Zometa ®, zoledronic acid, could prevent recurrence of breast cancer to nearly 800 women in Spain, as concluded by Dr. Michael Martin, president of the Spanish Group for Breast Cancer Research, GEICAM, from data provided by a study recently published in The New England Journal of Medicine. Dr. Martin explained that the treatment was tested in premenopausal women with hormone receptor-positive, and in absolute numbers, achieved a reduction of recurrence of 5%. Dr. Martin goes one step further and suggests that if the benefit of Zometa ® should also apply to postmenopausal women with hormone receptor-negative and could reduce the relapse rate by another 5%, which would mean that, a year in Spain, near 800 women could prevent relapse with this treatment, the doctor estimated.
In Spain are diagnosed each year between 17,000 and 20,000 breast cancer cases and 7000 deaths are recorded by this disease. In this context, Dr. Martin said that despite surgery and standard adjuvant therapy such as chemotherapy, hormone therapy or trastuzumab, it is estimated that 25% of women with breast cancer have a relapse in the future.
Hence the importance of this finding. Dr. Ana Lluch, Head of Service of Hematology and Medical Oncology, Hospital Clínico de Valencia, recognizing the great contribution they can make the administration of zoledronic acid for treatment of breast cancer. The rate of death in Spain because of this tumor has been reduced through early diagnosis programs, which can detect tumors at very initial stages and therefore the possibilities for treatment and cure are much higher. New treatments, taxanes, biological therapies such as trastuzumab, treatment with aromatase inhibitors, letrozole, anastrozole, and exemestane have also helped this reduction in relapse rate, says Dr. who is optimistic about future zoledronic acid injections.
So far, Zometa ® is indicated for the prevention of bone encumbrances arising from metastasis. However, the ABCSG-12 study has shown that zoledronic acid not only prevents locoregional recurrence, but systemic recurrence, such as lung or skin, which is what causes death, says Ana Lluch.
The study involved more than 1,800 premenopausal women with breast cancer in initial stage, after being subjected to curative surgery and treatment with goserelin to achieve ovarian suppression with hormonal therapy were treated with or without Zometa ® for three years. After a follow-up period with an average duration of 48 months, results showed that the addition of Zometa ® to hormone therapy (tamoxifen or anastrozole) reduced by 36% the risk of relapse or death.
Dr. Lluch explains that premenopausal women have a higher risk of relapse than postmenopausal women, especially systemic or distant relapse, since age is a pejorative factor. Postmenopausal women constitute 60% of patients with breast cancer in Spain, compared with 40% of premenopausal and therefore welcomes the fact that also other studies being developed for the application of zoledronic acid in postmenopausal women. We are convinced that zoledronic acid will also have a double effect on these women. He had already proven effective in increasing bone density, if confirmed to be effective in preventing relapse of breast cancer, could have an important place in the treatment of postmenopausal women.
For the doctor, who has a drug without significant side effects and also may reduce distant metastases, which help prevent bone loss in patients and decrease the risk of fracture is very important and we are transmitting to patients. Women from 50 to 55 years are concerned about a quality of life that will not have problems associated with bone fracture risk and this is where we can give good news.
Study characteristics
The study ABCSG-12 cooperative group Austrian Austrian Breast & Colorectal Cancer Study Group (ABCSG) is the first large clinical study, Phase III, randomized, reflecting that Zometa ® provides significant protection against recurrence of breast cancer in phase Initial in premenopausal women.
The ABCSG-12 is an open-label, multicentre joined 1803 premenopausal women with breast cancer estrogen receptor positive stage I or II, with involvement of fewer than 10 axillary lymph nodes. The patients were incorporated into the study after being subjected to curative surgery and initiation of treatment with goserelin for ovarian suppression, being randomly assigned to one of four study groups: (1) anastrozole over zoledronic acid, (2) anastrozole separately , (3) tamoxifen plus zoledronic acid, (4) tamoxifen alone. The treatment period was three years and the average follow up period was 48 months at the current analysis.
The primary endpoint of the four groups of study was disease-free survival or systemic recurrence. The locoregional recurrence-free survival, overall survival and bone mineral density were secondary endpoints.
With a mean follow up of 48 months, developments in disease-free survival or systemic recurrence was reduced by 36% (P = 0.01) and the risk of local recurrence-free events dropped by 35% (P = 0.02) Zometa ® added to hormone therapy compared with hormonal therapy alone. There were 16 deaths among patients who received Zometa ® with hormonal therapy, compared with 26 patients receiving hormonal sóloterapia, which entailed a nonsignificant reduction in risk of death in patients receiving Zometa ® compared with those received hormonal therapy alone (P = 0.11). A similar trend was observed in the reduction of bone metastases among patients receiving Zometa ® compared with those who received hormone therapy alone (P = 0.22). You will need longer follow-up and a larger number of events to determine if there are significant differences between groups in overall survival and survival free of bone metastasis. In general, treatment was well tolerated and side effects were consistent with the known safety profile of medicamento1.
About Zometa ®
Zometa ®, zoledronic acid, is indicated for the prevention of skeletal related events (pathological fractures, spinal cord compression, radiation or surgery to bone) in patients with advanced malignancies involving bone, and for the treatment of hypercalcemia induced by tumor. Zometa ® is approved and indicated for the treatment of patients with advanced tumors involving bone. Zometa ® is approved and indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases in solid tumors, along with the usual antineoplastic therapy. Zometa ®, an intravenous bisphosphonate, is the only treatment able to show efficacy in reducing or delaying bone complications in various types of tumors such as breast, prostate, lung and renal cell cancer, administering monthly in patients with metastatic disease. Zometa ® provides patients, health professionals and medical practice 15 minutes infusion.
Zometa ® is the leading treatment worldwide for the prevention or delay of skeletal related events (SREs) in patients with advanced tumors with bone involvement in a wide variety of tumors. The laboratory research has suggested that zoledronic acid could also help to protect patients in the spread of cancer to other parts of the body (distant metastases areas) and help keep patients recurrence-free, although not approved indication for Zometa ®.
Zometa ® slows the bone-destroying effect that occurs with bone metastases, combating abnormal activation of osteoclasts, cells that normally deteriorate old bone, and osteoblasts, cells that normally participate in the development of new bone. Growth factors produced by cancer cells on osteoclasts and stimulate osteoblasts, causing excessive erosion of bone and / or the accumulation of new bone, but unstable.
Important Safety Information
In clinical studies, the safety profile with Zometa ® was similar to that of pamidronate. Zometa ® has been associated with reports of kidney failure. Patients should be monitored serum creatinine level before receiving each dose of Zometa. Caution is advised when Zometa ® use in patients sensitive to aspirin or with aminoglycosides, loop diuretics, and other potentially nephrotoxic drugs. Due to the risk of clinically significant deterioration in renal function, single doses of Zometa ® should not exceed 4 mg. and duration of infusion should not be less than 15 minutes in 100ml. diluent.
In clinical studies in patients with bone metastases and hypercalcemia of malignancy, Zometa ® had a safety profile similar to other oral bisphosphonates. The most frequently reported adverse events were flu-like syndrome (fever, arthralgias, myalgias, skeletal pain), fatigue, gastrointestinal reactions, anemia, weakness, cough, dyspnea and edema. Zometa ® should not be used during pregnancy. Zometa ® is contraindicated in patients with clinically significant hypersensitivity to zoledronic acid or other bisphosphonates, or any of the excipients in the formulation of Zometa ®.
Osteonecrosis of the jaw (ONJ): ONJ has been reported of patients with cancer receiving treatment including bisphosphonates, chemotherapy and / or corticosteroids. Most reported cases have been associated with dental procedures like dental extractions. It should consider a dental examination with appropriate preventive dental care before treatment with bisphosphonates in patients with concomitant risk factors. During treatment, these patients should avoid invasive dental procedures whenever possible. We have no data to suggest whether the cessation of bisphosphonate therapy reduces the risk of ONJ in patients requiring dental procedures.
In Spain it is estimated that 25% of women with breast cancer who have been operated and subjected to standard adjuvant therapies, will have a relapse
Currently the drug is only indicated for prevention of complications of bone metastases, although research points to its ability to prevent relapses in other organs also
Treatment with Zometa ®, zoledronic acid, could prevent recurrence of breast cancer to nearly 800 women in Spain, as concluded by Dr. Michael Martin, president of the Spanish Group for Breast Cancer Research, GEICAM, from data provided by a study recently published in The New England Journal of Medicine. Dr. Martin explained that the treatment was tested in premenopausal women with hormone receptor-positive, and in absolute numbers, achieved a reduction of recurrence of 5%. Dr. Martin goes one step further and suggests that if the benefit of Zometa ® should also apply to postmenopausal women with hormone receptor-negative and could reduce the relapse rate by another 5%, which would mean that, a year in Spain, near 800 women could prevent relapse with this treatment, the doctor estimated.
In Spain are diagnosed each year between 17,000 and 20,000 breast cancer cases and 7000 deaths are recorded by this disease. In this context, Dr. Martin said that despite surgery and standard adjuvant therapy such as chemotherapy, hormone therapy or trastuzumab, it is estimated that 25% of women with breast cancer have a relapse in the future.
Hence the importance of this finding. Dr. Ana Lluch, Head of Service of Hematology and Medical Oncology, Hospital Clínico de Valencia, recognizing the great contribution they can make the administration of zoledronic acid for treatment of breast cancer. The rate of death in Spain because of this tumor has been reduced through early diagnosis programs, which can detect tumors at very initial stages and therefore the possibilities for treatment and cure are much higher. New treatments, taxanes, biological therapies such as trastuzumab, treatment with aromatase inhibitors, letrozole, anastrozole, and exemestane have also helped this reduction in relapse rate, says Dr. who is optimistic about future zoledronic acid injections.
So far, Zometa ® is indicated for the prevention of bone encumbrances arising from metastasis. However, the ABCSG-12 study has shown that zoledronic acid not only prevents locoregional recurrence, but systemic recurrence, such as lung or skin, which is what causes death, says Ana Lluch.
The study involved more than 1,800 premenopausal women with breast cancer in initial stage, after being subjected to curative surgery and treatment with goserelin to achieve ovarian suppression with hormonal therapy were treated with or without Zometa ® for three years. After a follow-up period with an average duration of 48 months, results showed that the addition of Zometa ® to hormone therapy (tamoxifen or anastrozole) reduced by 36% the risk of relapse or death.
Dr. Lluch explains that premenopausal women have a higher risk of relapse than postmenopausal women, especially systemic or distant relapse, since age is a pejorative factor. Postmenopausal women constitute 60% of patients with breast cancer in Spain, compared with 40% of premenopausal and therefore welcomes the fact that also other studies being developed for the application of zoledronic acid in postmenopausal women. We are convinced that zoledronic acid will also have a double effect on these women. He had already proven effective in increasing bone density, if confirmed to be effective in preventing relapse of breast cancer, could have an important place in the treatment of postmenopausal women.
For the doctor, who has a drug without significant side effects and also may reduce distant metastases, which help prevent bone loss in patients and decrease the risk of fracture is very important and we are transmitting to patients. Women from 50 to 55 years are concerned about a quality of life that will not have problems associated with bone fracture risk and this is where we can give good news.
Study characteristics
The study ABCSG-12 cooperative group Austrian Austrian Breast & Colorectal Cancer Study Group (ABCSG) is the first large clinical study, Phase III, randomized, reflecting that Zometa ® provides significant protection against recurrence of breast cancer in phase Initial in premenopausal women.
The ABCSG-12 is an open-label, multicentre joined 1803 premenopausal women with breast cancer estrogen receptor positive stage I or II, with involvement of fewer than 10 axillary lymph nodes. The patients were incorporated into the study after being subjected to curative surgery and initiation of treatment with goserelin for ovarian suppression, being randomly assigned to one of four study groups: (1) anastrozole over zoledronic acid, (2) anastrozole separately , (3) tamoxifen plus zoledronic acid, (4) tamoxifen alone. The treatment period was three years and the average follow up period was 48 months at the current analysis.
The primary endpoint of the four groups of study was disease-free survival or systemic recurrence. The locoregional recurrence-free survival, overall survival and bone mineral density were secondary endpoints.
With a mean follow up of 48 months, developments in disease-free survival or systemic recurrence was reduced by 36% (P = 0.01) and the risk of local recurrence-free events dropped by 35% (P = 0.02) Zometa ® added to hormone therapy compared with hormonal therapy alone. There were 16 deaths among patients who received Zometa ® with hormonal therapy, compared with 26 patients receiving hormonal sóloterapia, which entailed a nonsignificant reduction in risk of death in patients receiving Zometa ® compared with those received hormonal therapy alone (P = 0.11). A similar trend was observed in the reduction of bone metastases among patients receiving Zometa ® compared with those who received hormone therapy alone (P = 0.22). You will need longer follow-up and a larger number of events to determine if there are significant differences between groups in overall survival and survival free of bone metastasis. In general, treatment was well tolerated and side effects were consistent with the known safety profile of medicamento1.
About Zometa ®
Zometa ®, zoledronic acid, is indicated for the prevention of skeletal related events (pathological fractures, spinal cord compression, radiation or surgery to bone) in patients with advanced malignancies involving bone, and for the treatment of hypercalcemia induced by tumor. Zometa ® is approved and indicated for the treatment of patients with advanced tumors involving bone. Zometa ® is approved and indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases in solid tumors, along with the usual antineoplastic therapy. Zometa ®, an intravenous bisphosphonate, is the only treatment able to show efficacy in reducing or delaying bone complications in various types of tumors such as breast, prostate, lung and renal cell cancer, administering monthly in patients with metastatic disease. Zometa ® provides patients, health professionals and medical practice 15 minutes infusion.
Zometa ® is the leading treatment worldwide for the prevention or delay of skeletal related events (SREs) in patients with advanced tumors with bone involvement in a wide variety of tumors. The laboratory research has suggested that zoledronic acid could also help to protect patients in the spread of cancer to other parts of the body (distant metastases areas) and help keep patients recurrence-free, although not approved indication for Zometa ®.
Zometa ® slows the bone-destroying effect that occurs with bone metastases, combating abnormal activation of osteoclasts, cells that normally deteriorate old bone, and osteoblasts, cells that normally participate in the development of new bone. Growth factors produced by cancer cells on osteoclasts and stimulate osteoblasts, causing excessive erosion of bone and / or the accumulation of new bone, but unstable.
Important Safety Information
In clinical studies, the safety profile with Zometa ® was similar to that of pamidronate. Zometa ® has been associated with reports of kidney failure. Patients should be monitored serum creatinine level before receiving each dose of Zometa. Caution is advised when Zometa ® use in patients sensitive to aspirin or with aminoglycosides, loop diuretics, and other potentially nephrotoxic drugs. Due to the risk of clinically significant deterioration in renal function, single doses of Zometa ® should not exceed 4 mg. and duration of infusion should not be less than 15 minutes in 100ml. diluent.
In clinical studies in patients with bone metastases and hypercalcemia of malignancy, Zometa ® had a safety profile similar to other oral bisphosphonates. The most frequently reported adverse events were flu-like syndrome (fever, arthralgias, myalgias, skeletal pain), fatigue, gastrointestinal reactions, anemia, weakness, cough, dyspnea and edema. Zometa ® should not be used during pregnancy. Zometa ® is contraindicated in patients with clinically significant hypersensitivity to zoledronic acid or other bisphosphonates, or any of the excipients in the formulation of Zometa ®.
Osteonecrosis of the jaw (ONJ): ONJ has been reported of patients with cancer receiving treatment including bisphosphonates, chemotherapy and / or corticosteroids. Most reported cases have been associated with dental procedures like dental extractions. It should consider a dental examination with appropriate preventive dental care before treatment with bisphosphonates in patients with concomitant risk factors. During treatment, these patients should avoid invasive dental procedures whenever possible. We have no data to suggest whether the cessation of bisphosphonate therapy reduces the risk of ONJ in patients requiring dental procedures.
Alcohol and cigarettes cause cancer cases is increasing in the UK
Alcohol and cigarettes cause cancer cases is increasing in the UK
A study conducted by the UK Cancer Research Foundation of alcohol use in the country doubled since 1950, was revealed.
Alcohol use in terms of human health risks associated with large pointed out that the Cancer Research Foundation, the alcohol because the lips, mouth, tongue and throat cancer at a rate of 26 percent increase in the number caught was emphasized. The report also ride in the UK every year 800 people died from cancer because of the alcohol was attention. Alcohol also causes cancer of the cervix in the report as an important influence, "Oral cancer, 75 percent caught smoking and drinking alcohol comes from." was said. Evaluate the results of the Professor. Dr. Ian Gilmore, "These results showed that substances such as alcohol and cigarettes are not only older people are at risk for people of all ages." said.
A study conducted by the UK Cancer Research Foundation of alcohol use in the country doubled since 1950, was revealed.
Alcohol use in terms of human health risks associated with large pointed out that the Cancer Research Foundation, the alcohol because the lips, mouth, tongue and throat cancer at a rate of 26 percent increase in the number caught was emphasized. The report also ride in the UK every year 800 people died from cancer because of the alcohol was attention. Alcohol also causes cancer of the cervix in the report as an important influence, "Oral cancer, 75 percent caught smoking and drinking alcohol comes from." was said. Evaluate the results of the Professor. Dr. Ian Gilmore, "These results showed that substances such as alcohol and cigarettes are not only older people are at risk for people of all ages." said.
Subscribe to:
Posts (Atom)
